On July eleven, Glenmark Pharmaceuticals and Torrent Pharmaceuticals said they have got entered right into a licensing agreement to co-market diabetes drug Remogliflozin Etabonate in India.
“Under the terms of the agreement, Glenmark will receive an in advance charge, license costs, and royalties for the non-specific sub-license rights from Torrent.
“Glenmark will manufacture and deliver Remogliflozin while Torrent will marketplace the drug below its own trademark ‘Educator’ in India,” Glenmark Pharma stated in a regulatory submitting.
The agency but did not reveal the economic info of the licensing settlement.
Glenmark Pharma said in April 2019 it had acquired approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after efficaciously completing segment-3 clinical trials wherein the drug tested maximum efficacy and protection profile in a head-to-head comparison towards Dapagliflozin.
Subsequently, Glenmark released Remogliflozin, indicated in Type 2 Diabetes Mellitus treatment in adults underneath the emblem names ‘Remo’ and ‘Rozen’.
“The burden of diabetes in India is growing at an alarming charge, and via this collaboration, we intend to enhance get admission to to the present day, novel and globally- researched sodium-glucose co-transporter-2 (SGLT2) inhibitor through presenting a powerful, high fine and global-class remedy option to patients in India,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan stated.
“This partnership may also lay the foundation for a long-time collaboration with Torrent for Remogliflozin in phrases of its extra line extensions and further medical development,’ he delivered.
Dhruv Gulati, Executive Director (India & ROW), Torrent Pharma, said, “The drug will augment the Type 2 Diabetes Mellitus treatment armamentarium in the u. S., And this partnership could be an essential step closer to enhancing get entry to to the growing wishes of diabetic patients.”
The Central Drugs Laboratory in Kolkata performed tests on two special masses of the J&J child shampoo after the employer contested the Rajasthan Drugs Control Organisation (RDCO) that claimed to have discovered formaldehyde within the shampoo.
The RDCO on its website posted effects of the exams accomplished using Central Drugs Laboratory, which said that “the sample does now not contain formaldehyde” in each the lots.
The outcome reaffirms the agency’s testing and the longstanding assurance it gave that its toddler shampoo does now not incorporate formaldehyde or any formaldehyde-liberating substances, the corporation said.
“Importantly, this is the result of the appellate laboratory, following a Justice of the Peace Court docket order for re-testing, and overrules an earlier check result that changed into faulty,” the spokesperson said.
The agency said that nothing is extra vital to Johnson & Johnson than the protection of people who use its products, and the company’s quality guarantee system is rigorous – meeting or exceeding standards in every country where its products are offered.
In a June three, 2019 order to all Drug Control Officers of Rajasthan, the RDCO said that as in step with the check record of the Kolkata laboratory, samples of Johnson & Johnson’s infant shampoo one hundred ml and 50 ml did no longer comprise formaldehyde.
According to professionals, formaldehyde can purpose most cancers in humans.
On March five, 2019, the Rajasthan Drugs Control Organization reported formaldehyde in samples of two batches of baby shampoo manufactured by Johnson & Johnson in India.
The corporation had rejected the finding and said its merchandise no longer comprises formaldehyde or any component able to free formaldehyde. It wondered what the Rajasthan drug controllers declared, and the checking-out approach brought about the outcomes.
